Cellectar Biosciences, Inc.

CLRB

Cellectar Biosciences, Inc.

CLRB

Insider Sentiment (TTM):

Last Purchase:2026-05-07Last Sale:2025-12-12Shares Purchased (TTM):17,360Shares Sold (TTM):198

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:310,720Shares Outstanding:4,240,129Institutional Ownership Pct.:7.33%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Series E4 Preferred Stock	-	-	-	-	-	-	-	0	-	-	-	-
Assets Current
Cash And Cash Equivalents At Carrying Value	34	8	13	13	11	14	23	34	26	40	10	19
Prepaid Expense And Other Assets Current	1	1	1	1	2	1	1	2	2	1	1	1
Assets Current	35	9	14	14	13	15	24	36	28	41	10	20
Property Plant And Equipment Net	0	0	1	1	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	1	1	0	0	0	0	0	0	0	0	1	1
Long Term Investments	-	-	-	-	-	-	-	-	-	0	0	0
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	37	11	15	15	14	16	25	37	29	43	12	22
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	5	5	4	4	5	4	8	8	6	7	9	8
Derivative Liabilities Current	0	0	0	1	1	2	2	12	9	21	16	9
Operating Lease Liability Current	0	-	0	0	0	0	0	0	0	0	0	0
Series D Preferred Stock	-	-	-	-	-	-	-	-	-	0	0	-
Liabilities Current	5	5	5	5	6	6	9	20	15	29	25	16
Operating Lease Liability Noncurrent	2	2	0	0	0	0	0	0	0	0	0	1
Liabilities	7	6	5	5	6	6	10	21	16	29	26	17
Temporary Equity
Temporary Equity Carrying Amount Attributable To P…	-	-	-	-	-	-	-	-	-	1	1	18
Stockholders Equity
Preferred Stock Value	-	1	-	1	1	-	-	-	-	-	-	1
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	312	278	277	271	265	262	261	247	235	225	183	195
Retained Earnings Accumulated Deficit	-282	-275	-269	-264	-259	-254	-247	-245	-230	-229	-203	-210
Stockholders Equity	30	3	9	8	6	8	14	15	12	13	-15	-28
Liabilities And Stockholders Equity	37	11	15	15	14	16	25	37	29	43	12	22
Temporary Equity Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	-	-	0
Temporary Equity Shares Authorized	-	-	-	-	-	-	-	-	-	0	0	0
Temporary Equity Shares Issued	-	-	-	-	-	-	-	-	-	0	0	0
Temporary Equity Shares Outstanding	-	-	-	-	-	-	-	-	-	0	0	0
Preferred Stock Par Or Stated Value Per Share	-	-	-	-	-	-	-	-	-	-	-	0
Preferred Stock Shares Authorized	-	-	-	0	0	-	-	-	-	0	-	0
Preferred Stock Shares Issued	-	-	-	0	0	-	-	-	-	-	-	0
Preferred Stock Shares Outstanding	-	-	-	0	0	-	-	-	-	-	-	0
Series D Convertible Preferred Stock	-	0	0	0	0	0	0	0	0	-	1	-
Series E3 Preferred Stock	-	-	-	-	-	-	-	0	-12	12	-	-
Series E2 Preferred Stock	-	0	0	-	-	0	0	-0	0	0	0	-
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	170	170	170	170	170	170	170	170	170	170	170	160
Common Stock Shares Issued	8	4	4	3	2	2	2	1	1	1	1	0
Shares Outstanding	8	4	4	3	2	2	2	1	1	1	1	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-19.06%	-12.19%	-20.94%	-	-	-	-	-	-	-	-	-
2025	50.00%	-33.33%	-34.44%	12.67%	30.77%	-23.30%	31.36%	20.91%	12.20%	-6.90%	-4.83%	10.34%
2024	4.72%	-24.84%	-37.74%	-22.93%	-88.29%	-88.29%	-85.31%	-84.18%	-83.05%	-13.33%	-10.00%	-13.33%
2023	-	-	-	30.67%	77.91%	62.58%	28.02%	30.92%	81.64%	-16.76%	-9.34%	-11.54%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	6.66	1.90	2.96	2.77	2.15	2.47	2.58	1.77	1.84	1.45	0.41	1.22
Quick Ratio	6.49	1.71	2.78	2.56	1.88	2.31	2.48	1.69	1.71	1.40	0.38	1.15
Working Capital	29.64M	4.39M	9.29M	8.71M	6.75M	8.87M	14.86M	15.58M	12.74M	12.82M	-14.91M	3.64M
Leverage & Debt
Debt to Equity	0.23	1.92	0.59	0.66	1.02	0.78	0.69	1.37	1.26	2.32	-1.71	-0.61
Interest Coverage TTM	-57.89	-61.95	-52.82	-51.63	-48.93	-44.92	-42.76	-46.64	-56.81	-72.49	-100.64	-85.58
Debt Ratio	0.18	0.58	0.34	0.36	0.45	0.40	0.38	0.56	0.53	0.68	2.14	0.79
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-1.83	-4.92	-8.35	-5.96	-18.07	-15.98	-36.01	-37.77	-42.43	-63.67	-108.51	-123.98
Free Cash Flow Per Share TTM	-1.59	-4.38	-8.86	-9.41	-21.56	-28.48	-39.12	-35.57	-38.61	-40.36	-81.68	-82.08
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-23.21%	-15.09%	-51.12%	-62.38%	-45.11%	-60.56%	0.95%	7.33%	43.23%	81.75%	38.90%	70.99%
EPS Growth (1Y)	-89.90%	-69.24%	-77.12%	-84.40%	-59.26%	-74.90%	-66.34%	-69.18%	-55.02%	-30.26%	-19.81%	-7.62%
Valuation Metrics
P/E TTM	-1.52	-0.52	-0.35	-0.94	-0.39	-0.60	-0.25	-1.68	-1.69	-1.88	-0.77	-0.64
P/B TTM	1.14	3.23	0.90	2.21	1.88	1.79	0.77	5.55	7.23	9.33	-2.23	-1.07
Market Cap	34.00M	10.77M	7.69M	17.71M	11.44M	14.75M	10.99M	84.18M	89.55M	116.68M	33.82M	29.83M
Enterprise Value	10.56K	2.42M	-5.50M	5.15M	397.53K	840.38K	-12.30M	49.92M	63.68M	76.65M	24.25M	10.84M
Calculated Values
Free Cash Flow TTM	-19.48M	-18.58M	-23.12M	-29.75M	-34.68M	-43.75M	-47.75M	-46.64M	-46.09M	-39.44M	-33.24M	-30.91M
Net Debt	-33.99M	-8.35M	-13.20M	-12.55M	-11.04M	-13.91M	-23.29M	-34.26M	-25.87M	-40.03M	-9.56M	-18.99M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-07Purchase

Owner: Caruso, James V

Title: Chief Executive Officer

Shares: 8,680

Price/Share: $2.88

Value: $24,998.40

Shares Owned: 20,318

Relationship: Director,Officer

Ownership: Direct

2026-05-07Purchase

Owner: Longcor, Jarrod

Title: Chief Operating Officer

Shares: 8,680

Price/Share: $2.88

Value: $24,998.40

Shares Owned: 20,451

Relationship: Officer

Ownership: Direct

2025-12-12Sale

Owner: Neis, John

Title: -

Shares: 198

Price/Share: $3.70

Value: $732.60

Shares Owned: 10

Relationship: Director

Ownership: Indirect

2025-07-02Purchase

Owner: Kolean, Chad J

Title: Chief Financial Officer

Shares: 5,000

Price/Share: $4.99

Value: $24,950.00

Shares Owned: 6,418

Relationship: Officer

Ownership: Direct

2025-07-02Purchase

Owner: Caruso, James V

Title: Chief Executive Officer

Shares: 10,000

Price/Share: $4.99

Value: $49,900.00

Shares Owned: 11,638

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-07	Caruso, James V	Director,Officer	Chief Executive Officer	Direct	Purchase	8,680	2.88	$24,998.40	20,318	4
2026-05-07	Longcor, Jarrod	Officer	Chief Operating Officer	Direct	Purchase	8,680	2.88	$24,998.40	20,451	4
2025-12-12	Neis, John	Director	-	Indirect	Sale	198	3.70	$732.60	10	4
2025-07-02	Kolean, Chad J	Officer	Chief Financial Officer	Direct	Purchase	5,000	4.99	$24,950.00	6,418	4
2025-07-02	Caruso, James V	Director,Officer	Chief Executive Officer	Direct	Purchase	10,000	4.99	$49,900.00	11,638	4
2025-07-02	Longcor, Jarrod	Officer	Chief Operating Officer	Direct	Purchase	10,000	4.99	$49,900.00	12,768	4
2025-01-10	Longcor, Jarrod	Officer	Chief Operating Officer	Direct	Purchase	30,000	0.28	$8,400.00	83,141	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

7.33%

Inst. Shares: 310,720

Shares Outstanding: 4,240,129

2025-12-31

13.30%

Inst. Shares: 346,838

Shares Outstanding: 2,608,317

2025-09-30

9.36%

Inst. Shares: 296,115

Shares Outstanding: 3,162,040

2025-06-30

5.63%

Inst. Shares: 90,570

Shares Outstanding: 1,608,799

2025-03-31

Inst. Shares: 4,974,886

Shares Outstanding: 1,535,995

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	310,720	4,240,129	7.33%
2025-12-31	346,838	2,608,317	13.30%
2025-09-30	296,115	3,162,040	9.36%
2025-06-30	90,570	1,608,799	5.63%
2025-03-31	4,974,886	1,535,995	-
2024-12-31	5,044,103	1,220,749	-
2024-09-30	13,884,578	1,311,197	-
2024-06-30	11,412,524	1,193,981	-
2024-03-31	8,690,449	29,346,679	29.61%
2023-12-31	8,604,081	12,221,571	70.40%
2023-09-30	1,436,679	11,308,738	12.70%
2023-06-30	1,514,174	11,261,217	13.45%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Cellectar Biosciences, Inc. (CLRB) — SEC Financial Statements & Analysis

Cellectar Biosciences, Inc. (CLRB) is a pharmaceutical preparations company, incorporated in DE. Cellectar Biosciences, Inc. trades on Nasdaq as: CLRB. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Cellectar Biosciences, Inc. reported a Debt-to-Equity ratio of 0.23x, a Price-to-Book (P/B) ratio of 1.14x (TTM), at a market cap of $34.00M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.23x
P/B TTM: 1.14x
Market Cap: $34.00M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Cellectar Biosciences, Inc. in?

Cellectar Biosciences, Inc. (CLRB) operates in the Pharmaceutical Preparations industry.

What is CLRB's market cap?

Cellectar Biosciences, Inc. (CLRB) has a market capitalization of $34.00M as of 2026-06-30.

What exchange does CLRB trade on?

Cellectar Biosciences, Inc. (CLRB) trades on the Nasdaq.

Where is Cellectar Biosciences, Inc. incorporated?

Cellectar Biosciences, Inc. is incorporated in DE.